Key statistics
As of last trade, Apellis Pharmaceuticals Inc (1JK:STU) traded at 17.67, 22.31% above the 52 week low of 14.44 set on May 16, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 17.49 |
|---|---|
| High | 17.85 |
| Low | 17.15 |
| Bid | 17.68 |
| Offer | 17.76 |
| Previous close | 17.66 |
| Average volume | 444.44 |
|---|---|
| Shares outstanding | 127.83m |
| Free float | 110.15m |
| P/E (TTM) | 167.64 |
| Market cap | 2.65bn USD |
| EPS (TTM) | 0.1235 USD |
Data delayed at least 15 minutes, as of Mar 02 2026.
More ▼
- Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors
- Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
- Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
- Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting
- Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results
- Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
- Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
- The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
- Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
- Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years
More ▼
